Scientists track immunotherapy side effects to make cancer treatment safer

NCT ID NCT05331066

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 cancer patients starting immunotherapy (checkpoint inhibitors) to understand why some develop immune-related side effects. Researchers will collect blood samples and clinical data to find early warning signs. The goal is to improve how doctors monitor and manage these side effects, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors predict and manage side effects from immunotherapy, making cancer treatment safer and more personalized.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may take years to translate into clinical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    Chelsea, London, SW3 6JJ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••